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Abstract
Background: We carried out a technical evaluation of the 
Immunodiagnostic Systems (IDS) automated intact pro-
collagen-I N-terminus propeptide (PINP) assay on the iSYS 
platform, and established reference intervals for PINP in 
both adults and children.
Methods: Assay imprecision, recovery and interference 
were studied. Serum and plasma values were compared, 
and PINP stability was assessed. Using 828 specimens, 
IDS iSYS intact PINP and Roche E170 total PINP values 
were compared. Specimens from 597 adults and 485 chil-
dren and adolescents were used to establish reference 
intervals for intact PINP.
Results: The method demonstrated good recovery and 
acceptable imprecision. The assay was unaffected by 
icterus and lipaemia, but haemolysis decreased measured 
PINP. Serum and plasma values were comparable. There 
was a non-linear relation between IDS intact and Roche 
total PINP values. Pre- and post-menopausal women 
had comparable PINP values, but there was a difference 
between women of different age groups. Serum PINP in 
men showed a decline in young age up to 45 years, but 
remained steady thereafter. Separate reference intervals 
were established for four age groups in women and for 
two age groups in men. Data for children were partitioned 
into four-year age groups, and these showed PINP to be 
high with no major gender differences until 12  years of 
age. Thereafter, values in females decreased in 13–16 years 
age groups and further in 17–20 years age groups, whereas 
PINP increased in boys of 13–16 years of age with a subse-
quent decline at 17–20 years.
Conclusions: The IDS iSYS PINP intact assay appears to 
be reliable. We have established gender- and age-related 
reference intervals for children and adults based on a rela-
tively large healthy North European population.
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Introduction
Type I collagen is the most abundant collagen in con-
nective tissues, but its overall synthesis is highest in the 
bone, where it forms most of the tissue’s organic matrix. 
Its precursor, procollagen I, is synthesised by osteoblasts, 
and the terminus propeptides of the molecule are cleaved 
off extracellularly. Procollagen-I N-terminus propeptide 
(PINP) is 35 kDa, and is cleared by the hepatic endothe-
lium. Its circulating concentration correlates with osteo-
blastic activity, which is normally coupled to osteoclastic 
bone resorption [1]. Although there is no convincing evi-
dence that serum PINP concentrations can predict bone 
fracture [2], its measurement has been used to monitor 
the efficacy of anti-resorptive treatment in patients with 
osteoporosis [3]. Furthermore, PINP has also been recom-
mended for use as a bone formation marker in observa-
tional studies and intervention trials.
As with type I collagen from which it is cleaved, PINP 
is a heterotrimer [4]. Intact PINP assays detect solely this 
form, whereas total PINP assays also detect monomers 
or possibly fragments of PINP, although these molecules 
have not been characterised well [5]. An automated total 
PINP immunoassay (Roche Diagnostics) has been avail-
able for some years [6], and in 2009, an automated chemi-
luminometric immunoassay for intact PINP was made 
available by Immunodiagnostic Systems Ltd (IDS) on their 
iSYS analyser. An evaluation of this assay and analyser 
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was undertaken recently by Koivula et al., who also evalu-
ated the intact PINP assay results in patients with renal 
failure, and compared the values with those obtained 
by the Roche E170 total PINP assay [7]. In the current bi-
centre study, we have carried out additional independent 
evaluations of the iSYS intact PINP assay, and have estab-
lished reference intervals for both children and adults.
Materials and methods
Subjects and specimen collections
Blood specimens were collected at two study centres: Liège, Belgium, 
and Oxford, UK. For establishing reference intervals, specimens were 
collected from healthy children and adults with no history of bone 
disease according to ethically-approved local protocols. No criterion 
related to food intake was used for the specimen collections.
In Liège, the specimens were collected during normal working 
hours between Oct 2010 and May 2011. Serum was separated within 
1 h of collection, aliquots stored at −80°C, and parathyroid hormone 
(PTH), 25(OH)-vitamin D [25(OH)D] and creatinine were measured 
(v.i.). After exclusion of specimens with a PTH that was outside the 
reference interval (4–26 pg/mL; Diasorin 1-84 PTH assay), a 25(OH)
D concentration of  < 75 nmol/L, or an estimated glomerular filtration 
rate (eGFR) of  < 60 mL/min/1.73 m2, a total of 382 specimens from 
adults over 20 years of age, and 496 samples from children and ado-
lescents up to the age of 20 years were identified. The adults’ speci-
mens were from 140 men (median age 57 years; range 21–94 years), 
114 pre-menopausal (median age 36 years; range 21–49 years) and 
128 menopausal women (median age 65.5 years; range 54–88 years).
In Oxford, blood specimens were collected from 08.30 to 15.00 h 
between September 2009 and March 2010, and serum and plasma 
were separated within 2 h of collection, aliquots stored at −20°C. The 
specimens were from 198 apparently healthy adults, comprising 106 
men (median age 48 years; range 18–62 years), 72 pre-menopausal 
(median age 31.5 years; range 19–50 years) and 20 post-menopausal 
women (median age 57 years; range 51–69). Creatinine and 25(OH)
D status were assessed retrospectively. All measurements of alkaline 
phosphatase and albumin-adjusted calcium gave normal values. 
Separately and solely for an assessment of the relationship between 
PINP and renal function, data on 167 consecutive specimens that had 
been collected routinely for both PINP and creatinine measurements 
from patients attending osteoporosis clinics were collected.
Assays
In Liège, 25(OH)D was measured by the use of the DiaSorin total 
25(OH)D assay (DiaSorin, Stillwater, MN, USA) on a Liaison® analyser 
[coefficient of variation (CV)  < 12.8% at a 25(OH)D of  > 15 nmol/L]. 
Parathyroid hormone was measured by the DiaSorin two-site, chemi-
luminometric 1-84 assay kit, also on a Liaison® analyser (CV  < 10% at 
a PTH of  > 4.0 pmol/L). Creatinine was measured enzymatically by a 
Roche Modular analyser (Roche, Mannheim, Germany) (CV  < 6.1% at 
a creatinine of  > 80 nmol/L), and eGFR was calculated according to 
the abbreviated Modification of Diet in Renal Disease (MDRD) equa-
tion [175 × (Creat/88.4)−1.154 × (Age)−0.203 × (0.742 if female)]. Calcium was 
also measured on a Roche Modular analyser by the o-cresophthalein 
complexone method (CV  < 2.1% at a calcium of  > 1.55 mmol/L).
In Oxford, 25(OH)D was measured by the use of the IDS com-
petitive, chemiluminometric assay on the iSYS analyser [8] (CV  < 15% 
at a 25(OH)D of  > 23 nmol/L). Creatinine was measured by the use of 
a kinetic Jaffe method on a Siemens Advia® 2400 analyser (Siemens 
Healthcare Diagnostics Ltd, Frimley, UK) (CV  < 4.4% at a creatinine 
of  > 53 nmol/L), and eGFR was calculated according to the abbrevi-
ated MDRD equation. Calcium was measured by arsenazo III method, 
also on an Advia® 2400 analyser (total CV for adjusted calcium  < 5.8% 
at a calcium of  > 1.83 mmol/L and an albumin of  > 30 g/L).
PINP assays
IDS intact PINP kits were employed on iSYS analysers according to 
the manufacturer’s protocol. The two-site chemiluminometric assay 
employed a two-point calibration in triplicate (top calibrant values 
around 135 μg/L), quality control materials in duplicate, and 20 μL 
of sample in singleton. Specimens that had PINP values above the 
assay range (2–230 μg/L) were diluted in specimens with low PINP 
concentrations. In each study centre, analyses of specimens for 
establishing reference intervals were carried out over several 
analytical batches and by the use of the method during routine 
analyses of clinical samples. Stored specimens were analyses within 
2 months of collection.
Total PINP was measured electrochemiluminometrically by the 
use of a Roche E170 automated analyser (Roche Diagnostics,  Burgess 
Hill, UK and Vivoord, Belgium). According to the manufacturer and 
as corroborated by other studies, the assay had a within- and be-
tween-calibration CVs of  < 3.7% and  < 2.9% [7].
For comparing the IDS iSYS and the Roche E170 PINP assay 
 results, 828 serum specimens from healthy individuals in Liège and 
osteoporotic patients in Oxford were used. The specimens were stored 
frozen as described above, and were analysed by the two assays in at 
least three batches in each centre within 1 month of collection.
Recovery and interference
Recovery was assessed by diluting five serum specimens with PINP 
concentrations of 122–218 μg/L up to five-fold in five serum speci-
mens that had PINP of 7.3–14.5 μg/L, and comparing the results with 
expected values. The effects of haemolysis, lipaemia and icterus were 
assessed by the addition of: 1) lysates of saline-washed red cells ( final 
haemoglobin concentration range of 0.02–0.5 g/L); 2) Intralipid® 
(Fresenius Kabi Ltd, Runcorn, UK) (final triglyceride concentration 
range of 1.7–33.8 mmol/L); or 3) icteric plasma (final bilirubin con-
centration range of 42.5–340 μmol/L), and comparing the obtained 
values with those expected.
Imprecision
Within-batch imprecision was assessed by 10 repeated analy-
ses of two specimens, and also by duplicate analysis of 51 clinical 
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 specimens. Between-batch imprecision was studied by analysing 
three quality control specimens over 1 year using at least 10 inde-
pendent calibrations and four different lots of reagents.
Matrix effect and PINP stability
Becton Dickinson blood sampling tubes with gel separator (SSTII for 
serum and PSTII for plasma) were used. Paired serum and lithium 
heparin plasma were analysed in 45 specimens in the same assay 
batch.
Stability of separated plasma specimens was assessed by 
 analysing 18 plasma samples, leaving them at room temperature 
(RT; circa 20°C) for 3 days and subsequently at 4°C for 4 days before 
reanalysis. Separately, aliquots of five clotted and four heparinised 
blood specimens were centrifuged: 1) immediately, or after being 
kept at RT for 2) 1 day or 3) 3 days. After each centrifugation, separat-
ed serum and plasma aliquots were frozen at −20°C. Separate serum 
and plasma aliquots of the same specimens that had been kept at RT 
for 3 days were also 4) stored at 4°C for a further 4 days before being 
frozen at −20°C. All frozen, stored aliquots were thawed and analysed 
in one assay batch.
In order to assess the effects of short-term storage at −20°C, a 
further 23 serum specimens were analysed (PINP range 7.8–87.3 
μg/L), and at least five of these samples were re-analysed in batch-
es after storage at −20°C for various lengths of time. Separately, the 
effects of freezing and thawing of specimens on measured PINP was 
studied by repeat analysis in one assay batch of 10 specimens (PINP 
range 28.5–12.3 μg/L) after a further two and four freeze-thaw cycles.
Statistical analyses
Data were analysed using Analyse-It software (Analyse-It®, Leeds, 
UK), as an add-on for Microsoft Excel. For stability and matrix 
effect evaluations using same calibration, differences between 
paired values were assessed by Student’s t-test. For assessment of 
long-term stability at −20oC using different calibrations, pairs of 
values were compared by repeated measures analysis of variance 
(ANOVA). PINP values obtained by different methods were com-
pared by Passing and Bablok regression [9], and cumulative sum 
linearity test was performed to investigate deviation from linearity 
between two sets of data. Confidence intervals (CI) of 95% were 
used to assess whether slope and intercept values were signifi-
cantly different from 1 and 0, respectively. Associations between 
PINP values and age or biochemical measures were assessed by 
linear regression. PINP values from adults in different age groups 
were compared by one-way ANOVA with Bonferroni correction for 
multiple comparisons. Differences between PINP values according 
to age, gender and also menopausal state in women were assessed 
by Mann-Whitney test. A probability of  < 5% was considered statis-
tically significant.
Shapiro-Wilk test was performed to assess whether distribu-
tions of values used for establishing reference intervals were nor-
mal. Where a distribution was non-Gaussian, either a logarithmic 
or a square-root transformation was employed in order to normalise 
the distribution (assessed by Shapiro-Wilk W normality test). Val-
ues that were less than median –(3 × IQR) or greater than median 
+(1.5 × IQR) were deemed outliers, and were considered for removal 
from the transformed values based on ad hoc assessments of the data 
(IQR = inter-quartile range). For establishing reference intervals, Ana-
lyse-It® software’s parametric method of calculation was used when 
transformation normalised the data. The 95% reference interval and 
90% CIs of both the upper and lower limits were determined, and the 
calculated values were converted back to measured units. For non-
normalised data or when the number of observations was small, a 
non-parametric procedure was employed. Values were ranked, and 
the 2.5 and 97.5 percentiles were obtained as the 0.025 (n+1) and 0.975 




The assay showed average recoveries of between 89% and 
100% (SDs of 9.0%–17.4%). No trend in recoveries was 
observed at increasing dilution of up to five-fold.
Assay interference and matrix effects
No interference either from high triglycerides (recoveries 
of 97.4%–104.4%) or from high bilirubin concentrations 
(recoveries of 97.0%–103.7%) was observed. However, 
the addition of increasing amounts of haemolysate to 
serum specimens resulted in a significant and progressive 
decrease in measured PINP. Although an average PINP 
decrease of 1.5% at a haemoglobin concentration of 0.6 
g/L was negligible, the assay under-estimated PINP by 
averages (SD) of 5% (8.5%), 11% (4.5%), 18% (8.3%) and 
33% (10.3%) at haemoglobin concentrations of 0.5, 1.5, 2.5 
and 5.0 g/L, respectively.
PINP concentrations in plasma were higher than 
those in serum due to a significant proportional bias 
(p = 0.0091; plasma PINP = (1.06 × serum PINP)+1.0). 
However, the mean difference between the two values 
was only 1.2 μg/L (95% CI 0.3–2.2 μg/L over a serum 
PINP range of 17.5–90.8 μg/L), making the difference in 
values between the two types of specimen not clinically 
significant.
Imprecision
The within-batch imprecision was 3.6% at a PINP con-
centration of 22.4 µg/L, and 4.7% at 123.3 µg/L. Between-
batch imprecision at PINP concentrations of 18.0, 45.6 and 
115.8 µg/L were 7.2%, 8.5% and 7.0%, respectively.
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Stability
Heparinised plasma specimens left at RT for 3  days 
resulted in an average decrease in measured PINP of 5.5% 
(95% CI 3.3%–7.7%). Although this difference was sig-
nificant (p = 0.0001), it was within the assay’s between-
batch imprecision. No significant difference was observed 
between PINP values of serum or plasma that was sepa-
rated and frozen immediately and either: 1) serum or 
plasma of the same blood that was left unseparated at RT 
for a period of up to 3 days (p = 0.955), or 2) the same serum 
or plasma that was left at 4°C for a further 4 days (p = 0.736 
compared with controls).
The effects of storage of specimens at −20°C for 
various lengths of time have been described in Table 1. 
Storage of specimens at −20°C for up to 133 days did not 
have any significant effect on PINP results (p > 0.056). The 
mean CVs of pairs of values obtained at the outset and 
after storage for up to 133 days were comparable with the 
between-batch CV of the assay, and there was no consist-
ent trend in values over time. However, storage of serum 
(n = 11) at −20°C for 2.5  years resulted in an increase in 
measured PINP of +41.3% (SD = 34.8%; p < 0.0001). Freez-
ing and thawing of specimen did not have any significant 
effect on measured PINP. After three and five freeze-thaw 
cycles, PINP measured in the same analytical batch 
changed by averages of −1.2% (SD = 3.5%; p = 0.245) and 
−1.5% (SD = 4.7%; p = 0.167) compared with values after 
one freeze-thaw cycle.
Comparison with the Roche E170 total PINP 
assay
For comparisons between IDS iSYS and Roche E170 
PINP assays, 828 pairs of values were used. In the case 
of eight pairs of results, E170 gave much higher values 
compared with iSYS. The obtained intact and total PINP 
concentrations of these eight specimens were as follow 
(intact/total): 28/122, 66/196, 72/298, 643/6447, 667/6397, 
726/6097, 1406/7157 and 1341/5678 μg/L (range of ratios 
of total:intact = 3.0–10.0). No reason for the discrepancies 
was obvious (five healthy children with normal C-termi-
nus collagen type-I telopeptide values, two osteoporotic 
patients and one diabetic). For the remaining 820 speci-
mens (iSYS PINP concentration range of 6.5–2159 μg/L), 
the iSYS assay values were significantly higher than those 
obtained by the E170 (p < 0.0001). Figures 1 and 2 show 
the relationship between the values obtained by the two 
methods. The mean proportional and absolute biases 
of iSYS values compared with E170’s were +5% (95% CI 
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Figure 1 Relationship between IDS iSYS and Roche E170 PINP 
values obtained on 820 serum specimens (see text for the descrip-
tion of eight outliers that have not been shown).
Table 1 Stability of PINP in serum stored at −20°C.
Period stored 
at −20oC





36 days 7 +6.7 (10.5) 5.5 (5.6) 0.077
64 days 6 +2.0 (4.1) 2.4 (1.8) 0.128
87 days 6 +7.1 (10.4) 6.7 (4.4) 0.084
110 days 5 −7.4 (5.7) 5.6 (4.4) 0.057
133 days 6 −6.3 (7.2) 5.6 (4.2) 0.340
2.5 years 11 +41.3 (34.8) 18.9 (6.9)  < 0.0001
Stored specimens were assayed in separate batches at specified 
times. Mean percentage changes (and their SDs) relative to values 
obtained at the outset have been given. Mean CVs (and their SDs) 
for pairs of values, one obtained at the outset and the other at 
reanalysis after the specified periods, have also been given in order 
to allow comparisons with the between batch CVs of the assay 
(7.0%–8.5%).
4%–6%) and −1.4 μg/L (95% CI −0.8 to −1.9 μg/L), respec-
tively. However, the relationship between the two sets 
of values was non-linear (p < 0.0001; Figure  2’s inset), 
and at the low- and high-end total PINP concentrations 
of  < 100 μg/L and  > 670 μg/L, iSYS intact PINP assay gave 
lower values than E170 total PINP assay (p < 0.0001 at 
both these low and high concentration ranges). Overall, 
19.3% of iSYS values were  > 15% higher, and 8.8% of iSYS 
values were  > 15% lower, than the corresponding E170 
results.
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Assessment of PINP reference intervals
Relationship between PINP and other parameters
Assessment of the relationship between IDS iSYS PINP and 
25(OH)D in specimens from healthy volunteers in Oxford 
showed that there was no significant association between 
PINP and either 25(OH)D values [n = 187; p = 0.0821; r2 = 0.02; 
lowest 25(OH)D = 18.2 nmol/L; an average PINP increase 
of 0.7 μg/L for every 10 nmol/L increase in 25(OH)D], or 
albumin-adjusted calcium (p = 0.556; r2 = 0.00). Similarly, 
in healthy volunteers no significant association was found 
between iSYS PINP values and either creatinine (n = 187; 
p = 0.8276; r2 = 0.00; highest creatinine = 121 μmol/L) or eGFR 
(n = 186; p = 0.0728; r2 = 0.02 with positive slope; 6 values  < 60 
mL/min with mean (SD) PINP of 24.4 (11.1) μg/L; lowest 
eGFR = 53 mL/min/1.73 m2). Further investigation of the 
relationship between PINP and renal function using speci-
mens from 167 patients attending osteoporosis clinics also 
showed no significant association between PINP and either 
creatinine (p = 0.853; r2 = 0.00) or eGFR [p = 0.614; r2 = 0.00; 
median (IQR) eGFR = 75 (59–96) mL/min; lowest eGFR = 13 
mL/min]. Therefore, for establishing reference intervals for 
adults, the PINP data from all Oxford’s healthy volunteers 
were pooled with those from Liège.
PINP reference intervals in adults
Frequency distribution of PINP values showed a nega-
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Figure 2 Bland and Altman plot of the percentage difference 
between IDS-iSYS PINP and Roche E170 values relative to the mean 
(n = 820; see text for the description of eight outliers that have not 
been shown).
The inset depicts the deviation from the linear fit between the two 
sets of data according to mean PINP concentration.
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Figure 3 Serum PINP according to age in healthy females (A; 
n = 331) and by age group (B).
A value of 255 μg/L for an 80-year-old female has not been shown. 
n = 93, 87, 81 and 64 for women aged 18–35, 36–55, 51–65 and  > 65 
years, respectively.
transformation of PINP values normalised the distribu-
tion for pre-menopausal females (skewness = −0.04; kur-
tosis = −0.18; p = 0.612) and for males (skewness = −0.07; 
kurtosis = −0.16; p = 0.465), whereas a square-root trans-
formation was used for menopausal women’s values 
(skewness = 0.16; kurtosis = −0.65; p = 0.122). Assessment 
of the relationship between women’s serum PINP values 
and their age showed no association between the two 
(p = 0.459; Figure 3A). Pre- and post-menopausal women’s 
PINP values were not significantly different (p = 0.117), 
and reference intervals for these two groups have been 
given in Table 2A. However, when PINP concentrations 
were divided according to age groups 18–35, 36–50, 51–65 
and  > 65 years (Figure 3B), there was a significant differ-
ence between the four groups (p = 0.009). Comparing PINP 
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values from adjacent age groups showed that the only sig-
nificant difference was between those from 36 to 50 years 
and 51–65  years age groups (p = 0.006) (p > 0.070 for the 
other two comparisons). Table 2A also describes the refer-
ence intervals for women according to the four age groups.
Values in men decreased significantly with age 
(p < 0.0001; Figure 4A). In men aged  < 45 years, there was 
an average decrease in PINP of 4.6 μg/L (CI 1.8–7.3 μg/L) 
for each 5 years increase in age (p < 0.0014), and separat-
ing men’s PINP according to age (Figure 4B) showed that 
PINP values in 36–45 year olds (n = 31) was lower than in 
those aged 18–35 years (n = 46) (p < 0.0001). No significant 
0
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Figure 4 Serum PINP according to age in healthy males (A; n = 244) 
and by age group (B).
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Figure 5 Distribution of iSYS PNP values according to age in women 
(A) and men (B) in the two study centres, Liege and Oxford.
difference was found between PINP concentrations in age 
groups 46–55 and  > 55 (p = 0.174), and each of these groups 
had significantly lower PINP concentrations compared 
with men aged 18–45 years (p < 0.0001 for both compari-
sons). Therefore, reference limits were established for 
men aged 18–45 and  > 45 years (Table 2A).
Differences between PINP values from the two centres
Pre-menopausal women from Liège had significantly 
higher PINP concentrations than those from Oxford 
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(p = 0.035), but the differences in values were not sig-
nificant for the pre-menopausal women of 18–35  years 
(p = 0.086) and 36–50 years of age (p = 0.057). The values 
for post-menopausal women from Liège and Oxford 
were not different (p = 0.606). There was only one 
woman aged  > 65  years from Oxford, precluding com-
parison between the values in this age group from the 
two centres. Figure 5A compares women’s PINP values 
from the two study centres according to age. Men from 
Oxford also had lower serum PINP compared with men 
from Liège (p = 0.009). This difference was related to 
those aged 18–45 years (p = 0.001), and there was no dif-
ference between men aged  > 45 years from the two centres 
(p = 0.095) (Figure 5B).
PINP reference intervals in children and young adults
PINP values for males and females up to the age of 20 years 
were divided into 4-year age groups. This compromise 
allowed each age group to have at least 40 PINP values 
(except for n = 38 for group of males aged 17–20 years; 
Table 1B). The distributions of the values are presented in 
Figure 6. Frequency distribution of PINP values showed a 
significant kurtosis and a negative skew in all age groups, 
except for females aged 0–4 and 9–12 years, and males 
5–8 years. The upper limits of normal PINP for boys and 
girls were comparable up to, and including, the 9–12 year 
age group, but were higher for males in both the 13–16 
and 17–20 year groups. After 12 years of age, PINP values 
decreased in females, with both groups’ values showing a 
decrease in those 17–20 year age group. Table 1B describes 
the reference intervals for individuals aged up to 20 years.
Discussion
In this study, we evaluated the automated IDS intact PINP 
assay on the iSYS instrument. We found the assay to have 
good reproducibility, recovery and precision, and to be 
unaffected by icterus and lipaemia. However, haemoly-
sis caused a significant under-estimation of PINP, and 
caution should be exercised in reporting PINP results on 
haemolysed specimens. Our recovery and precision data 
agree well with those reported by Koivula et al., who also 
evaluated the IDS iSYS intact PINP assay [7]. By the use 
of gel-filtration studies, pooled sera and a haemodialysed 
serum, these authors found the assay to be specific for 
intact PINP.
Our data on stability of the PINP molecule detected 
by the assay suggest that the results are not affected by 
the general, common delays encountered during speci-
men transport from primary care, and by further delays 
in laboratory prior to analysis. These findings confirm 
earlier reports by Lomeo et al. that PINP has good stability 
compared with some other bone markers [10]. The com-
parability of results obtained on serum and heparinised 
plasma also provides robustness with respect to sample 
type. The analytical range of the iSYS assay (up to circa. 
230 μg/L) would allow the analysis of specimens from 
adults without a need for sample dilution, but makes it 
necessary to dilute most paediatric specimens before 
analysis. Repeated freezing and thawing of specimens 
did not have a significant influence on measured PINP 
values, and specimens stored at −20°C for up to 133 days 
gave PINP values that were not significantly different from 
10
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Figure 6 Distribution of iSYS PINP values according to age group in 
female (A) and male (B) children and young adults.
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the intact assay appears to be its specificity for PINP and 
its lack of cross-reactivity with the so-called monomeric 
or other forms [5, 12]. The identities of these molecules are 
unknown; they may be either pro-α1 chains or fragments 
of PINP, but they have also been reported to have a larger 
molecular weight than PINP [7]. The retention of some of 
these molecules in blood of patients with renal impairment 
can make the interpretation of some total PINP results dif-
ficult [5]. It has been suggested that the monomeric form 
detected by the total PINP assay may be a breakdown 
product of collagen, and in breast cancer patients, for 
example, PINP has been shown to be higher by the Roche 
E170 total PINP assay as compared with the IDS iSYS 
method [13]. Therefore, whether the detection of such PINP 
molecules by total PINP assays may offer some additional 
information in specific groups of patients, e.g. those with 
metastatic bone disease, remains unknown [14, 15].
In our study, we did not find a relationship between 
intact PINP and either creatinine, estimated GFR or 
those measured at the outset. However, long-term storage 
of specimens at this temperature caused an increase in 
measured PINP concentrations. Whether this represents 
a breakdown of trimeric or high-molecular-weight struc-
tures that expose α1 chain or other structures that cross-
react with the intact assay is not known [11].
Comparisons made between the iSYS intact and the 
Roche E170 total PINP assays showed a non-linear relation-
ship between the two sets of values. At both the range of 
values seen in adults and very high concentrations seen 
in some children ( < 100 and  > 670 μg/L), the iSYS PINP 
values were generally lower than those obtained by the 
E170 assay, with an opposite trend for values in-between. 
These data, together with the very large, unexplained dis-
crepancies observed in the case of eight specimens, suggest 
that although there is a broad, general agreement between 
the intact and total PINP assays, there are some variations 
between the two results, and the differences can be large, 
unpredictable and clinically significant. The advantage of 
Table 2 The upper and lower limit (UL and LL) of reference intervals established for IDS iSYS PINP in adults (A) and children (B). The oldest 





Lower limit 90% CI of 
lower limit
Upper limit 90% CI of 
upper limit
Pre-menopausal women All 180 13.7 12.6–15.0 71.1 65.2–77.7
18–35 93 14.7 13.0–16.6 74.6 66.1–84.1
36–50 87 12.9 11.4–14.6 66.8 58.8–75.8
Post-menopausal women All 145 8.2 6.2–10.4 82.6 86.0–89.5
51–65 81 9.0 6.2–12.3 87.7 78.5–97.5
 > 65 64 7.5 4.9–10.7 75.3 66.3–84.8
Men 18–45 77 19.4 17.0–22.1 95.4 83.8–108.7
 > 45 167 12.8 11.7–14.1 71.9 65.3–79.1
B










Children 0–4 F 44 619 468 174 1079
M 45 650 246 299 1010
5–8 F 56 584 220 307 985
M 53 524 199 200 900
9–12 F 48 691 291 386 1070
M 53 625 308 323 1242
13–16 F 54 175 225 59.3 672
M 43 754 1492 142 6929
17–20 F 51 62 24.9 25.2 160
M 38 113 79.6 28.1 369
All PINP values are in μg/L. CI, confidence interval; n, number.
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25(OH)D. Previously, no association between total PINP 
(Roche E170) and 25(OH)D had been found in an evalua-
tion of PINP reference intervals [16, 17]. Although serum 
PINP concentrations were not different between pre- 
and post-menopausal women, differences were present 
between age-specific subgroups. Therefore, we defined 
separate reference intervals for four age groups in women, 
and for pre- and post-menopausal women as a whole.
Age-related changes for total PINP have been reported 
previously. Studies in women have shown a decline in 
total PINP (Roche) with age until the eighth decade of life, 
when an increase in concentrations have been reported 
[16, 18]. However, Glover et al. found that whereas PINP 
in women decreased between the ages 30 and 35 years, it 
was stable over the age range 35 and 45 years [19]. Other 
bone markers have shown an increase during post-men-
opausal years [20]. The decline in bone markers until 
middle-age has been suggested to be due to an increase 
in skeletal maturity [21], whereas their increase in old age 
may be attributed, at least in part, to a decrease in gonadal 
hormones, which play a crucial role in maintaining bone 
mass. Both the use of oral contraceptives and oestrogen 
replacements have been shown to lower serum concentra-
tions of PINP and other bone markers [19, 21–24]. Recker 
et al. showed an increase in bone remodelling after men-
opause [25], and changes in bone markers during the 
menstrual cycle have also been documented [21]. One 
limitation of our study, therefore, is that we were unable 
to exclude women on exogenous oestrogens or establish 
reference intervals accordingly.
We observed a progressive decrease in PINP in men 
with increasing age up to 45 years. This decrease may be 
related to gonadal hormone levels, and Leder et al. found 
that suppressing androgens and oestrogens in men aged 
22–44  years increased PINP and other bone markers 
[26]. However, others have reported only a weak relation 
between PINP and testosterone in young men, with a much 
stronger inverse association between PINP and oestrogens 
[27, 28]. Our cohort of men aged  < 45 years was too small 
to allow establishing reference intervals according to nar-
rower age bands in this group, and a larger study popu-
lation will be needed for this purpose. Our PINP data in 
older men are in agreement with those reported by Olmos 
et  al., who found no change in total PINP (Roche) with 
age in men  > 50 years old [17]. Since there was no differ-
ence in PINP between subgroups of men aged  > 45 years, 
we defined reference intervals for  ≤  45 and  > 45 years age 
groups.
Our findings that young men and women from Oxford 
had lower PINP concentrations than those from Liège are 
similar to those of Glover et al., who reported a lower PINP 
in women from the UK than in those living in Belgium and 
France [21]. Although these differences are not very large, 
the data highlight the variability of circulating PINP con-
centrations in different populations, and the need to exer-
cise caution when adopting reference intervals derived 
from a different population.
PINP values obtained in children were divided into 
4-year age groups. This was a compromise, but allowed 
(with the exception of aged 17–20 males) evaluations of 
groups with at least 40 PINP values in each. We found the 
limits of normal PINP values to be not too dissimilar in 
boys and girls up to the age of 12 years. For 13–16  years 
age groups, PINP decreased in girls, and declined further 
at 17–20  years of age. By contrast, PINP increased for 
13–16-year-old boys, before decreasing, but not quite 
reaching adult levels, at 17–20 years of age. These fluctua-
tions are consistent with those previously observed with 
PINP and other bone-formation markers [29, 30]. As with 
other bone-markers, the magnitude of changes in PINP 
during growth in children, as well as the large inter-indi-
vidual variations at each age, impose limitations on defin-
ing the limits of normality with a high degree of certainty 
in this group of individuals.
In summary, our findings have shown the IDS intact 
PINP assay to be reliable, precise, and unaffected by 
pre-analytical variables other than haemolysis. Using 
a relatively large cohort of adults and children, we have 
established reference intervals for use in these groups 
according to gender and age, and these intervals have 
been employed in our laboratories. Further work is 
required in particular to define reference intervals accord-
ing to age in men  < 45 years of age, as well as those in chil-
dren according to Tanner stage. To our knowledge these 
data are amongst the largest available for establishing ref-
erence intervals for PINP.
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